Document:

EX-10.9

 Exhibit 10.9 

CYTEK BIOSCIENCES, INC. 

2021 AMENDED AND RESTATED SEVERANCE BENEFIT PLAN 

AND 
 SUMMARY PLAN
DESCRIPTION 
 (Effective January 1, 2020; as amended and restated on _____________, 2021) 

1. Introduction. The purpose of this Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan (the
“Plan”) is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare
benefit plan,” as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether
written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for severance benefits upon the Covered Employee’s separation from the
Company. This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. 

2. Definitions. For purposes of the Plan, the terms below are defined as follows: 

2.1. “Administrator” means the Board or Compensation Committee prior to a Change in Control; or, after a Change in Control,
one or more members of the successor Board or Compensation Committee or other persons designated by the Board or Compensation Committee prior to such Change in Control. 

2.2. “Board” means the Board of Directors of the Company. 

2.3. “Cause” means the termination of a Covered Employee’s employment with the Company or its subsidiaries due to
(i) commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof (or local laws for international Covered Employees, as applicable); (ii) attempted commission of,
or participation in, a fraud or act of dishonesty against the Company; (iii) intentional, material violation of any contract or agreement between the Covered Employee and the Company or of any statutory duty owed to the Company;
(iv) unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) gross misconduct. The determination that a termination of the Covered Employee’s employment is either for Cause or without
Cause will be made by the Company, in its sole discretion. 
 2.4. “Change in Control” shall be as defined in the
Company’s 2021 Equity Incentive Plan (as amended or amended and restated from time to time, the “2021 Plan”), other than with respect to changes to the Incumbent Board (as defined in the 2021 Plan), which shall not apply. 

2.5. “Change in Control Period” means the time period beginning on the date that is three (3) months prior to when a
Change in Control becomes effective and ending on the first anniversary of the effective date of such Change in Control. 
 2.6.
“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 
 2.7. “Company”
means Cytek Biosciences, Inc. and any successor. 

 2.8. “Compensation Committee” means the Compensation Committee of the
Board. 
 2.9. “Covered Employee” means an employee of the Company (i) with a title of Vice President or above, or
(ii) if not covered by (i), has been designated by the Board to participate in the Plan, provided that in each case, such employee has timely and properly executed and delivered a Participation Agreement to the Company. 

2.10. “Covered Termination” means a Covered Employee’s termination of the employment either (i) at any time, by the
Company (or any parent or subsidiary of the Company) without Cause or (ii) during the Change in Control Period, by such Covered Employee for Good Reason. 

2.11. “Effective Date” means _____________, 2021. 

2.12. “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 

2.13. “Good Reason” means the Covered Employee’s resignation from all positions the Covered Employee then holds with the
Company (and all parents and subsidiaries of the Company) within 30 days following expiration of the cure period for the following events taken without the Covered Employee’s express written consent, provided that the Covered Employee has given
the Board written notice of such event within 90 days after the first occurrence of such event setting forth the basis for the Covered Employee’s resignation and the Company has not reasonably cured such event within 30 days after the
Board’s receipt of such written notice: 
 (i) a material reduction in the Covered Employee’s duties or responsibilities, provided
that neither (A) a change in title nor (B) a change in the Covered Employee’s reporting relationships, in either case, by virtue of the Company being acquired or made part of a larger entity will be deemed a “material
reduction” in and of itself; 
 (ii) a material reduction in the Covered Employee’s base salary, unless such reduction is made in
connection with a similar action affecting all senior executives of the Company; or 
 (iii) a relocation of the Covered Employee’s
principal place of employment to a place that increases the Covered Employee’s one-way commute by more than 50 miles as compared to the Covered Employee’s then-current principal place of employment
immediately prior to such relocation. 
 2.14. “Participation Agreement” means the individual agreement (as will be
provided in separate cover as Appendix A) provided by the Administrator to a Covered Employee under the Plan, which has been signed and accepted by the Covered Employee. 

2.15. “Severance Benefits” means the compensation and other benefits the Covered Employee will be provided pursuant to either
Section 4 or 5, as applicable. 
 2.16. “Termination Date” means the Covered Employee’s last day of employment
with the Company. 
 2.17. “Tier 1 Covered Employee” means the Chief Executive Officer of the Company. 

2.18. “Tier 2 Covered Employee” means a Covered Employee who is not the Chief Executive Officer of the Company. 

 3. Eligibility for Severance Benefits. An individual is eligible for severance
benefits under the Plan, in the amounts set forth in Sections 4 and 5, only if such individual is a Covered Employee as of the consummation of a Change in Control or during the three month period prior to a Change in Control, and remains an employee
of the Company or an affiliate of the Company on the date such individual experiences a Covered Termination. 
 4. Severance
Benefits. 
 4.1. Covered Termination Outside of the Change in Control Period. If, at any time other than during the Change in
Control Period, a Covered Employee experiences a Covered Termination, then, subject to such Covered Employee’s compliance with Section 6, such Covered Employee shall receive the following Severance Benefits from the Company: 

4.1.1. Cash Severance Benefits. The Covered Employee shall receive cash severance in an amount equal to the Covered Employee’s
base salary for the number of months set forth below: 
 Tier 1 Covered Employee: 9 months 

Tier 2 Covered Employee: 6 months 
 The cash
amount shall be paid in a single lump sum payment on the 60th day following the Termination Date. 

4.1.2. COBRA Premiums. Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation
coverage pursuant to COBRA, the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee’s dependents) for such coverage following the date of the Covered Employee’s Covered Termination for up to the number
of months set forth below (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee’s
dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company promptly after the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered
Employee’s dependents are no longer eligible for COBRA coverage. 
 Tier 1 Covered Employee: 9 months 

Tier 2 Covered Employee: 6 months 

5. Change in Control Severance Benefits. 

5.1 Covered Termination During the Change in Control Period. If, at any time during the Change in Control Period, a Covered Employee
experiences a Covered Termination, then, subject to the Covered Employee’s compliance with Section 6, the Covered Employee shall receive the following Severance Benefits from the Company: 

5.1.1. Cash Severance Benefits. The Covered Employee shall receive cash severance in an amount equal to: 

(i) the Covered Employee’s base salary (as in effect immediately prior to any reduction giving rise to Good Reason) for the number of
months set forth below: 
 Tier 1 Covered Employee: 24 months 

Tier 2 Covered Employee: 12 months; and 

 (ii) 100% of such Covered Employee’s bonus target for the year in which such
termination occurs. 
 The cash amount shall be paid in a single lump sum payment on the 60th day
following the Termination Date. 
 5.1.2. COBRA Premiums. Provided the Covered Employee is eligible for and timely makes the
necessary elections for continuation coverage pursuant to COBRA the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee’s dependents) for such coverage following the date of the Covered Employee’s
Covered Termination for up to the number of months set forth below (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee
and the Covered Employee’s dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent
employer or if the Covered Employee’s dependents are no longer eligible for COBRA coverage. 
 Tier 1 Covered Employee: 24 months 

Tier 2 Covered Employee: 12 months 

5.1.3. Equity Vesting. Each of the Covered Employee’s then outstanding equity awards shall accelerate and become vested and
exercisable as to 100% of the unvested shares subject to the equity award, except any award granted after the Effective Date that explicitly overrides this provision in writing. Subject to Section 6, the accelerated vesting described in this
paragraph shall be effective as of the Termination Date. For purposes of this Section 5.1.3, any equity awards subject to performance-based vesting shall accelerate based on target performance. Notwithstanding anything herein to the contrary,
nothing in the Plan shall limit the Company’s ability to accelerate vesting and/or exercisability of outstanding equity awards pursuant to the terms of the applicable equity incentive plan of the Company. 

6. Conditions to Receipt of Severance. 

6.1 Release Agreement. As a condition to receiving the Severance Benefits, a Covered Employee must sign a waiver and release of all
claims in favor of the Company and its subsidiaries and affiliates (the “Release”) in such form as may be provided by the Company. The Release will include specific information regarding the amount of time the Covered Employee will
have to consider the terms of the Release and return the signed agreement to the Company. 
 6.2 Other Requirements. A Covered
Employee’s receipt of Severance Benefits pursuant to Section 4 or 5 will be subject to such Covered Employee continued material compliance with the terms of the Release, the Participation Agreement, any confidential information agreement,
proprietary information and inventions agreement and any other agreement between the Covered Employee and the Company. Severance Benefits under this Plan shall terminate immediately for a Covered Employee if such Covered Employee is in material
violation, at any time, of any legal or contractual obligation owed to the Company. 
 6.3 Section 280G. Any provision of the Plan to
the contrary notwithstanding, if any payment or benefit a Covered Employee would receive from the Company and its subsidiaries or an acquiror pursuant to the Plan or otherwise (a “Payment”) would (i) constitute a
“parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will
be equal to the Higher Amount (defined below). The “Higher Amount” will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest
portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate),
results in Covered Employee’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise

 
Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Higher Amount, reduction will occur in the manner that results
in the greatest economic benefit for a Covered Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. In no event will the Company, any subsidiary or any stockholder be
liable to any Covered Employee for any amounts not paid as a result of the operation of this Section 6.3. The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to
provide its calculations, together with detailed supporting documentation, to a Covered Employee and the Company within 15 calendar days after the date on which such Covered Employee’s right to a Payment is triggered (if requested at that time
by such Covered Employee or the Company) or such other time as requested by such Covered Employee or the Company. 
 7. Non-Duplication of Benefits. Notwithstanding any other provision in the Plan to the contrary, the Severance Benefits provided to a Covered Employee are intended to be and are exclusive and in lieu of any other
severance and change in control benefits or payments to which such Covered Employee may otherwise be entitled, either at law, tort, or contract, in equity, or under the Plan, in the event of any termination of such Covered Employee’s
employment. The Covered Employee will be entitled to no severance or change in control benefits or payments upon a termination of employment that constitutes a Covered Termination other than those benefits expressly set forth herein and those
benefits required to be provided by applicable law or as negotiated in accordance with applicable law (including any severance benefits that may be included in a severance agreement, employment agreement or similar contract between the Company or a
subsidiary of the Company and the Covered Employee). Notwithstanding the foregoing, if a Covered Employee is entitled to any benefits other than the benefits under the Plan by operation of applicable law or as negotiated in accordance with
applicable law, such Covered Employee’s benefits under the Plan shall be provided only to the extent more favorable than such other arrangement. The Administrator, in its sole discretion, shall have the authority to reduce or otherwise adjust a
Covered Employee’s benefits under the Plan, in whole or in part, by any other severance benefits, pay and benefits in lieu of notice, or other similar benefits payable to such Covered Employee under the Plan that become payable in connection
with the Covered Employee’s termination of employment pursuant to (i) any applicable legal requirement, including the Worker Adjustment and Retraining Notification Act (the “WARN Act”), the California Plant Closing Act or
any other similar state law, or (ii) any policy or practice of the Company providing for the Covered Employee to remain on payroll for a limited period of time after being given notice of termination. The benefits provided under the Plan are
intended to satisfy, in whole or in part, any and all statutory obligations of the Company that may arise out of a Covered Employee’s termination of employment, and the Plan Administrator shall so construe and implement the terms of the Plan.

 8. Section 409A. Notwithstanding anything to the contrary in the Plan, no severance payments or benefits will become payable until
the Covered Employee has a “separation from service” within the meaning of Section 409A of the Code and the final regulations and any guidance promulgated thereunder (“Section 409A”). Further, if
some or all of the Covered Employee’s Severance Benefits are subject to Section 409A and such Covered Employee is a “specified employee” within the meaning of Section 409A at the time of such Covered Employee’s
separation from service (other than due to death), then such Severance Benefits otherwise due to such Covered Employee on or within the six-month period following such Covered Employee’s separation from
service will accrue during such six-month period and will become payable in a lump sum payment (less applicable withholding taxes) on the date six months and one day following the date of the Covered
Employee’s separation from service if necessary to avoid adverse taxation under Section 409A. All subsequent payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding
anything herein to the contrary, if the Covered Employee dies following such Covered Employee’s separation from service but prior to the six-month anniversary of such Covered Employee’s date of
separation, then any 

 
payments delayed in accordance with this paragraph will be payable in a lump sum (less applicable withholding taxes) to the Covered Employee’s estate as soon as administratively practicable
after the date of such Covered Employee’s death and all other benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under the Plan is intended to constitute a
separate payment for purposes of Section 409A. It is the intent of this Plan to comply with or be exempt from the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to
the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under the Plan comply with
Section 409A, and in no event shall the Company or any of its representatives be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Covered Employee on account of non-compliance with Section 409A. 
 9. Withholding. The Company will withhold from any
Severance Benefits all federal, state, local and other taxes required to be withheld therefrom and any other required payroll deductions. 

10. Administration. The Plan will be administered and interpreted by the Administrator (in the Administrator’s sole discretion).
The Administrator is the “named fiduciary” of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to
the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. Any decision made or other
action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document that (i) does not affect the benefits payable under the Plan shall not be
subject to review unless found to be arbitrary and capricious or (ii) does affect the benefits payable under the Plan shall not be subject to review unless found to be unreasonable or not to have been made in good faith. 

11. Amendment or Termination. The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any
time, without advance notice to any Covered Employee and without regard to the effect of the amendment or termination on any Covered Employee or on any other individual. Any amendment or termination of the Plan will be in writing. Notwithstanding
the foregoing, a Covered Employee’s rights to receive payments and benefits pursuant to this Plan in connection with a Covered Termination during a Change in Control Period may not be adversely affected, without the Covered Employee’s
written consent, by an amendment or termination of this Plan occurring during such Change in Control Period. Unless sooner terminated by the Administrator, the Plan will automatically terminate on the tenth anniversary of the Effective Date. 

12. Claims Procedure. Claims for benefits under the Plan shall be administered in accordance with Section 503 of ERISA and the
Department of Labor Regulations thereunder. Any employee or other person who believes they are entitled to any payment under the Plan (a “claimant”) may submit a claim in writing to the Administrator within 90 days of the earlier of
(i) the date the claimant learned the amount of such claimant’s severance benefits under the Plan or (ii) the date the claimant learned that they will not be entitled to any benefits under the Plan. In determining claims for benefits,
the Administrator or its delegate has the authority to interpret the Plan, to resolve ambiguities, to make factual determinations, and to resolve questions relating to eligibility for and amount of benefits. If the claim is denied (in full or in
part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice will also describe any additional information or material that
the Administrator needs to complete the review and an explanation of why such information or material is necessary and the Plan’s procedures for appealing the denial (including a statement of the applicant’s right to bring a civil action
under Section 502(a) of ERISA following a denial on review of the claim, as described below). The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time (up to 90 days),
written notice of 

 
the extension will be given to the claimant (or representative) within the initial 90-day period. This notice of extension will indicate the special
circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim. If the extension is provided due to a claimant’s failure to provide sufficient information, the time frame for
rendering the decision will be tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information. The Administrator has delegated the claims review
responsibility to the Company’s Chief Executive Officer or such other individual designated by the Administrator, except in the case of a claim filed by or on behalf of the Company’s Chief Executive Officer or such other individual
designated by the Administrator, in which case, the claim will be reviewed by the Chair of the Company’s Board of Directors. 
 13.
Appeal Procedure. If the claimant’s claim is denied, the claimant (or such claimant’s authorized representative) may apply in writing to an appeals official appointed by the Administrator (which may be a person, committee or other
entity) for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of a claim denial or else the claimant will lose the right to such review. A request for
review must set forth all the grounds on which such request is based, all facts in support of the request, and any other matters that the claimant feels are pertinent. In connection with the request for review, the claimant (or representative) has
the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit written comments, documents, records and other information relating to such claimant’s claim. The
review shall take into account all comments, documents, records and other information submitted by the claimant (or representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit
determination. The appeals official will provide written notice of its decision on review within 60 days after it receives a review request. If special circumstances require an extension of time (up to 60 days), written notice of the extension will
be given to the claimant (or representative) within the initial 60-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the appeals
official expects to render its decision. If the extension is provided due to a claimant’s failure to provide sufficient information, the time frame for rendering the decision on review is tolled from the date the notification is sent to the
claimant about the failure to the date on which the claimant responds to the request for additional information. If the claim is denied (in full or in part) upon review, the claimant will be provided a written notice explaining the specific reasons
for the denial and referring to the provisions of the Plan on which the denial is based. The notice shall also include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all
documents and other information relevant to the claim and a statement regarding the claimant’s right to bring an action under Section 502(a) of ERISA. The Administrator has delegated the appeals review responsibility to the Company’s
Chief Executive Officer, except in the case of an appeal filed by or on behalf of the Company’s Chief Executive Officer, in which case, the appeal will be reviewed by the Chair of the Company’s Board of Directors. 

14. Arbitration. No arbitration proceeding shall be brought to recover benefits under the Plan until the claims procedures described in
Sections 12 and 13 have been exhausted and the Plan benefits requested have been denied in whole or in part. Notwithstanding any other provision of the Plan, to ensure the timely and economical resolution of disputes, all disputes, claims, or causes
of action arising from or relating to the enforcement, breach, performance or interpretation of this Plan will be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Fremont,
California, conducted by JAMS, Inc. (“JAMS”) under the then-applicable JAMS rules (available at the following web address: https://www.jamsadr.com/rules-employment). By agreeing to 

 
this arbitration procedure, each Covered Employee and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. Covered Employees will
have the right to be represented by legal counsel at any arbitration proceeding. In addition, all claims, disputes, or causes of action under this section, whether by a Covered Employee or the Company, must be brought in an individual capacity, and
shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more
than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found
unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to
award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to
award any or all remedies that a Covered Employee or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required of a Covered Employee if
the dispute were decided in a court of law. Nothing in this paragraph is intended to prevent either a Covered Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. Any arbitration must be commenced within one year after the Covered Employee’s
receipt of notification that their appeal was denied. The foregoing provisions shall apply to the extent consistent with and permitted by ERISA. 

15. Source of Payments. All severance benefits will be paid in cash from the general funds of the Company; no separate fund will be
established under the Plan, and the Plan will have no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company. 

16. Inalienability. In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell,
transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process. 

17. No Enlargement of Employment Rights. Neither the establishment nor maintenance of the Plan, any amendment of the Plan, nor the
making of any benefit payment hereunder, will be construed to confer upon any individual any right to be continued as an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without
cause. However, as described in the Plan, a Covered Employee may be entitled to benefits under the Plan depending upon the circumstances of such Covered Employee’s termination of employment. 

18. Successors. Any successor to the Company of all or substantially all of the Company’s business or assets (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company
would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term “Company” will include any successor to the Company’s business or assets which become bound by the terms of
the Plan by operation of law, or otherwise. 
 19. Applicable Law. The provisions of the Plan will be construed, administered and
enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the State of California (except its conflict of laws provisions). 

 20. Severability. If any provision of the Plan is held invalid or unenforceable, its
invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included. 

21. Headings. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning
hereof. 
 22. Additional Information. 
  

			
	Plan Name:	  	Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan
		
	Plan Sponsor:	  	Cytek Biosciences, Inc.
		  	46107 Landing Parkway
		  	Fremont, California 94538
		  	(877) 922-9835
		
	Identification Numbers:	  	EIN: 47-2547526
		
	Plan Year:	  	Company’s fiscal year ending December 31
		
	Plan Administrator:	  	Cytek Biosciences, Inc.
		  	Attention: Administrator of the Cytek Biosciences, Inc. 2021
		  	Amended and Restated Severance Benefit Plan
		  	46107 Landing Parkway
		  	Fremont, California 94538
		  	(877) 922-9835
		
	Agent for Service of Legal Process:	  	Cytek Biosciences, Inc.
		  	Attention: Administrator of the Cytek Biosciences, Inc. 2021
		  	Amended and Restated Severance Benefit Plan
		  	46107 Landing Parkway
		  	Fremont, California 94538
		  	(877) 922-9835
		
		  	Service of process may also be made upon the Administrator.
		
	Type of Plan:	  	Severance Plan/Employee Welfare Benefit Plan
		
	Plan Costs:	  	The cost of the Plan is paid by the Company.

 23. Statement of ERISA Rights. 

As a Covered Employee under the Plan, you have certain rights and protections under ERISA: 

(a) You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of
Labor. These documents are available for your review at the Company. 
 (b) You may obtain copies of all Plan documents and other Plan
information upon written request to the Administrator. A reasonable charge may be made for such copies. 
 In addition to creating rights
for Covered Employees, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan (called “fiduciaries”) have a duty to do so prudently and in the interests of you and the
other Covered Employees. No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for
a severance benefit is denied, in whole or in part, you have a right to know why it was denied, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. The claim review
procedure is explained in Section 12 and Section 13 above. 

 Under ERISA, there are steps you can take to enforce the above rights. For instance, if you
request a copy of Plan documents and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the
materials, unless the materials were not sent because of reasons beyond the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are
discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court
may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. 

If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your
rights under ERISA, you may contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security
Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits
Security Administration at 1-866-444-3272. 

 APPENDIX A 

CYTEK BIOSCIENCES, INC. 

2021 AMENDED AND RESTATED 

SEVERANCE BENEFIT PLAN 

Participation Agreement 

Cytek Biosciences, Inc. (the “Company”) is pleased to inform you, [name], that you have been selected to participate
in the Company’s 2021 Amended and Restated Severance Benefit Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all
of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan. 

In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to [name] no
later than [date]. 
 The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits
and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. 

In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the
Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 6.1 of the Plan. 

In accordance with Section 7 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you
related to your termination of employment with the Company and/or a change in control of the Company and will supersede and replace any severance and/or change in control benefits to which you otherwise would eligible to participate in any other
Company severance and/or change in control policy, plan, agreement or other arrangement (whether or not subject to ERISA). 
 By your
signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (i) you have received a copy of the Plan;
(ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 7 of the Plan; and (iii) decisions and determinations by the Administrator under
the Plan will be final and binding on you and your successors. 
  

									
	CYTEK BIOSCIENCES, INC.	 		  	COVERED EMPLOYEE
			
		 		  	
	Signature	 		  	Signature

									
					
	Name:	 	 	 		  	Name:	  	 

									
					
	Title:	 	 	 		  	Title:	  	 

									
					
	Date:	 	 	 		  	Date:	  	 

 Attachment: Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plancalm2021x10kex41

Exhibit 4.1 
To Annual Report 
on Form 10-K for Fiscal 2021 
Of Cal-Maine Foods, Inc. 
 

 

DESCRIPTION OF CAPITAL STOCK 
 
The amount of capital stock which Cal-Maine Foods, Inc. (the “Company” or “Corporation”) is authorized to issue (the “Capital 
Stock”) is 124,800,000 
shares, consisting of 
(a) 120,000,000 shares 
of Common 
Stock with a 
par value 
of One Cent 
($.01) per 
share and (b) 4,800,000 shares of Class A Common Stock with a par value of One Cent ($.01) per share. 
 
The 
following 
summary 
describes 
the 
Capital 
Stock 
under 
the 
Company’s 
Second 
Amended 
and 
Restated 
Certificate 
of 
Incorporation (the “Restated Charter”). 
The summary may not 
be complete and is subject 
to, and qualified in 
its entirety by, the 
applicable provisions 
of Delaware 
law and 
the terms and 
provisions of our 
Restated Charter. You 
should refer 
to, and 
read this 
summary together 
with, our 
Restated Charter 
to review 
all provisions 
applicable to 
our Capital 
Stock that 
may be important 
to 
you. 
 
Equal Treatment 
 
Except as otherwise provided in the Restated 
Charter as described below, or required by applicable 
law, shares of Common Stock 
and Class A 
Common Stock shall have the same rights and powers, rank equally (including as 
to dividends and distributions, and 
upon any 
liquidation, dissolution 
or winding 
up of 
the Corporation), 
share ratably 
and be 
identical in 
all respects 
and as 
to all 
matters. 
 
Voting Rights 
 
Holders of shares of Capital Stock vote as a single class on all matters submitted to a vote of the stockholders, with each share of 
Common Stock 
entitled to 
one vote 
and each 
share of 
Class A Common Stock 
entitled to 
ten votes. 
Holders of 
Capital Stock 
have the right of cumulative voting in the election of directors. 
Cumulative voting means that each stockholder is entitled to cast 
as many 
votes as 
he or 
she has the 
right to 
cast (before 
cumulating votes), 
multiplied by 
the number 
of directors 
to be 
elected, 
and such stockholder may cast all of such votes for a single director or may distribute them among the number to be voted for, or 
for any two or more of them as such stockholder may see fit. 
 
Under Delaware 
law, the affirmative 
vote of the 
holders of a 
majority of the 
outstanding shares of 
any class of 
Capital Stock is 
required to approve, among other 
things, any amendment to the 
certificate of incorporation that would 
alter or change the 
powers, 
preferences 
or special 
rights of 
such class 
so as 
to affect 
such class 
adversely. In 
addition, as 
long as 
any of 
the shares 
of the 
Class A Common 
Stock are 
outstanding, 
the consent 
of not 
less than 
66 2/3 
% of 
the total 
shares of 
Class A Common 
Stock 
outstanding is required to 
(1) alter or change the rights 
and privileges of Class A Common Stock; (2) to 
amend any provision of 
Paragraph 4 of the Restated Charter affecting the Class A 
Common Stock or (3) effect any re-classification or re-capitalization of 
the Company’s Capital Stock. 
 
Dividends 
 
Holders of 
shares of 
Capital Stock 
are entitled 
to receive 
such dividends 
as may 
be declared 
by our 
Board of 
Directors out 
of 
funds legally available for such purpose. 
 
Shares of Common 
Stock and Class A Common Stock 
are required to 
be treated equally, 
identically and ratably, 
on a per 
share 
basis, with respect to any dividends or distributions as may be declared and paid from time to time by the Board of Directors out 
of any assets of the Company legally available therefor. 
 
However, in the event a dividend is paid in the form of shares of Capital Stock 
(or rights to acquire such shares), then holders of 
Common Stock shall receive 
shares of Common Stock 
(or rights) and holders of 
Class A Common Stock shall receive shares of 
Class A Common 
Stock (or 
rights), with 
holders of 
shares of 
Common Stock 
and Class A Common 
Stock receiving, 
on a 
per 
share basis, an identical number of shares of Common Stock or Class A Common Stock, as applicable. 

Exhibit 4.1 
To Annual Report 
on Form 10-K for Fiscal 2021 
Of Cal-Maine Foods, Inc. 
 

 

 
Notwithstanding the foregoing, the 
Board of Directors may 
pay or make 
a disparate dividend 
or distribution per share 
of Common 
Stock or Class A Common 
Stock (whether 
in the amount 
of such dividend 
or distribution payable 
per share, 
the form 
in which 
such dividend 
or distribution 
is payable, 
the timing 
of the 
payment, or 
otherwise) if 
such disparate 
dividend or 
distribution 
is 
approved in advance by the affirmative vote of the holders of a majority of the outstanding shares of Common Stock and 
Class A 
Common Stock, each voting separately as a class. 
 
Ownership of Class A Common Stock 
 
The Class A Common 
Stock may 
only be issued 
to Immediate 
Family Members 
and Permitted Transferees 
(each as 
defined in 
the 
Restated 
Charter, 
and 
as summarized 
below). 
In 
the 
event 
any 
share 
of 
Class A Common 
Stock, 
by 
operation 
of 
law 
or 
otherwise is, or 
shall be deemed 
to be owned 
by any person 
other than 
an Immediate Family 
Member or 
Permitted Transferee, 
such share of Class A Common Stock shall 
automatically convert into 
Common Stock, whereby the 
voting power of such 
stock 
would be reduced from ten votes per share to one vote per share. 

 
The term “Immediate Family Member” 
includes: the spouse of our 
late founder and Chairman 
Emeritus Fred R. 
Adams, Jr., (Mrs. 
Jean Adams), 
his 
natural 
children 
(the 
“Daughters”), 
his 
sons-in-law 
(including 
our 
Chairman 
and 
Chief 
Executive 
Officer 
Adolphus B. Baker), and his grandchildren, including the estates of all of 
such persons. 
 
The term “Permitted Transferee” includes: 
 
(i) 
an Immediate Family Member; 
 
(ii) 
a trust 
held for 
the sole 
or primary 
benefit of 
one or 
more Immediate 
Family Members 
or Permitted 
Transferees, 
including any trustee in such trustee’s capacity as such, provided 
that if a trust is not for the sole benefit of one or 
more 
Immediate 
Family 
Members 
or 
Permitted 
Transferees, 
an 
Immediate 
Family 
Member 
or 
Permitted 
Transferee 
must 
retain sole 
dispositive and 
exclusive power 
to direct 
the voting 
of the 
shares of 
Class A Common Stock 
held by 
such 
trust; 
 
(iii) 
a corporation, limited liability company or partnership, including but not limited to, a family limited partnership or 
similar limited liability 
company or corporation, 
or a single member 
limited liability company, 
provided that all 
of the 
equity interest in 
such entity is owned, 
directly or indirectly, by 
one or more Immediate 
Family Members or 
Permitted 
Transferees and an 
Immediate Family Member 
or Permitted Transferee retains 
sole dispositive and 
exclusive power to 
direct the voting of the shares of Class A Common Stock held by such entity; 

 
(iv) 
a qualified 
Individual Retirement 
Account, pension, 
profit sharing, 
stock bonus 
or other 
type of 
plan or 
trust of 
which an Immediate 
Family Member or Permitted 
Transferee is a participant 
or beneficiary, provided that 
in each case 
an Immediate Family Member or 
Permitted Transferee retains sole dispositive and 
exclusive power to direct the voting 
of the shares of Class A Common Stock held by such account, plan or trust; or 
 
(v) 
any guardianship, conservatorship or custodianship 
for the benefit of an Immediate Family 
Member who has been 
adjudged 
disabled, 
incapacitated, 
incompetent 
or 
otherwise 
unable 
to 
manage 
his 
or 
her 
own 
affairs 
by 
a 
court 
of 
competent jurisdiction, including any 
guardian, conservator or 
custodian in such guardian’s, 
conservator’s or custodian’s 
capacity as such. 
 
Other Provisions 
 
The holders of Common Stock and Class A Common Stock are not entitled to preemptive or subscription rights. 
 

Exhibit 4.1 
To Annual Report 
on Form 10-K for Fiscal 2021 
Of Cal-Maine Foods, Inc. 
 

 

Unless approved in advance by the affirmative vote of the holders of a majority of 
the outstanding shares of Common Stock and 
Class A Common 
Stock, 
each 
voting 
separately 
as 
a 
class, 
shares 
of 
Common 
Stock 
or Class 
A Common 
Stock 
may 
not 
be 
subdivided, combined 
or reclassified unless 
the shares of 
the other class 
are concurrently therewith 
proportionately subdivided, 
combined 
or 
reclassified 
in 
a 
manner 
that 
maintains 
the 
same 
proportionate 
equity 
ownership 
between 
the 
holders 
of 
the 
outstanding Common Stock and Class A 
Common Stock on the record date for such subdivision, combination or reclassification. 
 
Unless approved in advance by the affirmative vote of the holders of a majority of 
the outstanding shares of Common Stock and 
Class A Common 
Stock, each 
voting separately 
as a 
class, upon 
the dissolution, 
liquidation or 
winding up 
of the 
corporation, 
whether voluntary 
or involuntary, 
holders of 
Common Stock 
and Class A Common 
Stock will 
be entitled 
to receive 
ratably all 
assets of the Corporation available for distribution to its stockholders. 
 
In the event of 
(i) a merger, 
consolidation or other business 
combination requiring the approval of 
the holders of the 
Corporation’s 
capital stock entitled to vote thereon, (ii) a tender or exchange offer to acquire any shares of Common Stock or Class 
A Common 
Stock by a third party pursuant to 
an agreement to which the Corporation is 
a party, or (iii) a tender or exchange offer 
to acquire 
any 
shares of 
Common 
Stock or 
Class A Common 
Stock 
by the 
Corporation, 
holders of 
the 
Common 
Stock 
and 
the Class 
A 
Common Stock 
shall have the 
right to receive, 
or the right 
to elect to 
receive, the 
same form and 
amount of 
consideration on 
a 
per share basis. 

 
Each share 
of Class A Common 
Stock is 
convertible, at 
the option 
of its 
holder, into 
one share 
of Common 
Stock at 
any time. 

Once shares of Class A Common Stock 
are converted into Common 
Stock, the shares of 
Class A Common Stock will be retired 
and 
may not 
be reissued. 
The number 
of shares 
of Common 
Stock into 
which 
the shares 
of Class A 
Common 
Stock may 
be 
converted is 
subject to 
adjustment from 
time to 
time in 
the event 
of any 
capital reorganization, 
reclassification of 
stock of 
the 
Company or consolidation or merger of the Company with or into another corporation. 
 
The 
Restated 
Charter 
includes 
a 
sunset 
provision 
pursuant 
to 
which 
all 
of 
the 
outstanding 
Class 
A 
Common 
Stock 
will 
automatically 
convert 
to 
Common 
Stock 
if: 
(a) 
less 
than 
4,300,000 
shares 
of 
Class A 
Common 
Stock, 
in 
the 
aggregate, 
are 
beneficially owned by Immediate Family 
Members and/or Permitted Transferees, 
or (b) if less than 4,600,000 
shares of Class A 
Common Stock 
and Common Stock, 
in the aggregate, 
are beneficially owned 
by Immediate Family 
Members and/or Permitted 
Transferees. 
 
Control by Immediate Family Members, Anti-Takeover Considerations and Conflicts of Interest 
 
General 
 
Mr. Adams founded the Company 
and served as its CEO 
from the formation 
of the Company in 1969 
until 2010, when his son-
in-law, Mr. Baker, became CEO. Mr. Adams died on March 29, 2020. 
 
As of July 19, 2021, Immediate Family Members beneficially 
own all of the 4.8 million outstanding shares of Class A Common 
Stock, representing 52.1% of the total voting power, and approximately 5.1 million shares of Common Stock, representing 5.6% 
of the total voting power. 
Such persons possess in the aggregate 57.7% of the total voting power of the outstanding shares 
of our 
Common Stock and Class A Common Stock, based on shares held directly or through related entities. 
 
The Common 
Stock is 
listed on 
The Nasdaq 
Stock Market 
(“NASDAQ”). 
Because Mrs. 
Adams, 
Mr. Baker 
and Mr. 
Baker’s 
spouse beneficially 
own in 
the aggregate 
capital stock 
of the 
Company entitling 
them to 
57.7% of 
the total 
voting power, 
the 
Company 
is a 
“controlled 
company” under 
NASDAQ rules. 
As a 
controlled 
company, the 
Company is 
not subject 
to certain 
NASDAQ 
listing 
standards, 
such 
as 
those 
that 
would 
otherwise 
require 
that 
a 
majority 
of 
a 
listed 
company’s 
directors 
be 
independent 
and 
that 
a 
compensation 
committee 
and 
nominating 
committee 
of 
the 
board 
of 
directors 
composed 
solely 
of 
independent directors be 
established. 
The Company is, however, 
subject to NASDAQ listing 
standards requiring that the Audit 
Committee be composed solely 
of independent directors. Delaware 
law provides that 
the holders of 
a majority of 
the voting power 

Exhibit 4.1 
To Annual Report 
on Form 10-K for Fiscal 2021 
Of Cal-Maine Foods, Inc. 
 

 

of shares entitled to vote must approve certain fundamental corporate transactions such as a merger, consolidation and sale of all 
or substantially 
all of 
a corporation’s 
assets. 
Immediate Family 
Members currently 
hold a 
majority of 
the voting 
power of 
all 
shares of capital stock of the 
Company and have indicated that they 
intend to retain ownership of a sufficient 
amount of Common 
Stock and Class 
A Common Stock 
to assure continued ownership of 
more than 50% of the 
voting power of our 
outstanding shares 
of capital stock. 
Accordingly, a merger, consolidation, sale of 
all or substantially all of 
the assets or other business combination 
or 
transaction 
involving 
the 
Company, 
which 
requires 
a 
stockholder 
vote, 
cannot 
be 
effected 
without 
the 
approval 
of 
the 
Immediate Family Members. 
 
As a result, majority control may make an unsolicited acquisition of the 
Company more difficult and discourage certain types of 
transactions involving a change of control of our Company, including transactions in which the holders of Common Stock might 
otherwise 
receive a 
premium for 
their shares 
over then 
current market 
prices. 
Also, the 
controlling 
ownership 
of our 
Capital 
Stock 
by 
Immediate 
Family 
Members 
may 
adversely 
affect 
the 
market 
price 
of 
our 
Common 
Stock, 
due 
in 
part 
to 
lack 
of 
speculation that there may be a change in control. 
 
Delaware Anti-Takeover Law 
 
We 
are subject 
to Section 
203 (“Section 
203”) of 
the Delaware 
General 
Corporation 
Law. 
Under 
this provision, 
we may 
not 
engage 
in 
any 
“business 
combination” 
with 
any 
interested 
stockholder 
for 
a 
period 
of 
three 
years 
following 
the 
date 
the 
stockholder became an interested stockholder, unless: 
 
i.
 
prior to that date our Board of Directors approved either the business combination 
or the transaction that resulted in the 
stockholder becoming an interested stockholder; 
 
ii.
 
upon 
completion of 
the transaction 
that resulted 
in the 
stockholder becoming 
an interested 
stockholder, the 
interested 
stockholder owned at least 85% of the voting stock outstanding at the time the transaction began; 
or 
 
iii.
 
on or following 
that date, the busi
ness combination is 
approved by our Board 
of Directors and 
authorized at an 
annual 
or special meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock that 
is not owned 
by the interested stockholder. 
 
Section 203 defines “business combination” to include, subject to limited 
exceptions: 
 
i.
 
any merger or consolidation involving the corporation and the interested stockholder;
 
 
ii.
 
any sale, 
transfer, pledge 
or other 
disposition of 
10% or 
more of 
the assets 
of the 
corporation involving 
the interested 
stockholder; 
 
iii.
 
any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested
 
stockholder; 
 
iv.
 
any transaction 
involving the 
corporation 
that has 
the e
ffect of 
increasing the 
proportionate share 
of the 
stock of 
any 
class or series of the corporation beneficially owned by the interested stockholder; or 
 
v.
 
the receipt 
by the 
interested 
stockholder of 
the benefit 
of any 
loans, advances, 
guarantees, pledges
 
or other 
financial 
benefits provided by or through the corporation. 
 
In 
general, 
Section 203 
defines 
an 
“interested 
stockholder” 
as 
any 
entity 
or 
person 
beneficially 
owning 
15% 
or 
more 
of 
the 
outstanding voting 
stock of the 
corporation and 
any entity or 
person affiliated 
with or controlling 
or controlled 
by the entity 
or 
person. 

Exhibit 4.1 
To Annual Report 
on Form 10-K for Fiscal 2021 
Of Cal-Maine Foods, Inc. 
 

 

 
The restrictions of 
Section 203 of the 
Delaware General Corporation 
Law do not 
apply to corporations 
that have elected, 
in the 
manner provided therein, not to 
be subject to Section 
203 of the 
Delaware General Corporation Law. 
The Company has not 
made 
such an election. 
Accordingly, the Company would be subject to Section 203 in the event of a business combination. 

 
Transfer Agent
 
 
 
Computershare Trust Company of Louisville, Kentucky, is the Transfer Agent and Registrar for our Common Stock.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]